RenovoRx, Inc.

RNXT
$0.88 (- $0.01 - 0.72%)
Last updated: 2026-06-17 02:42 UTC
RNXT Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS75989R1077
CUSIP75989R107
Market Price0.88
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.35
Market Cap$32.8M
Book Value0.22
Price to Book4.07
Beta1.29
52w High1.69
52w Low0.7
Next Earnings DateN/A

RenovoRx, Inc. trades under ticker RNXT on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US75989R1077, CUSIP 75989R107.

About the Company
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Price History